MP Advisors, Jan 2011, Pages: 391
for the future, and their key milestones.
The Global Pharmaceutical Model is changing. Major pharmaceuticalcompanies continue to under-perform in a market constrained by patent expiry, generic competition
Business Monitor International, April 2011, Pages: 115
sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Company Profiles
Examining the competitive positioning and short- to medium-term business
Business Monitor International, March 2011, Pages: 116
companyanalyses and rankings by US$ sales, % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Company Profiles Examining
Business Monitor International, March 2011, Pages: 95
provides comparative companyanalyses and rankings by US$ sales, % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Company Profiles
Business Insights, March 2008, Pages: 280
eleven of the world’s top twenty biotechnology companies currently attain a positive net income. This trend is a key industry-wide issue, with companies now attempting to stabilize financial performance
Business Monitor International, Aug 2011, Pages: 89
of pharmaceuticals (compared with the rest of developed Europe) is a clear illustration of the need for innovative medicines. However, the performance of the pharmaceutical market remains indelibly tied to the country
Datamonitor, July 2010, Pages: 207
Fosamax is positioned as the market gold standard
SWOT analysis
Brand forecast to 2019
Fosamax Plus D fails to maintain market share upon alendronate generic penetration in the US
Bisphosphonates
GlobalData, Nov 2010, Pages: 436
of the current and future market competition in the global Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players
GlobalData, April 2011, Pages: 335
.4 Hoffmann-La Roche Ltd.
9.4.1 Business Description
9.4.2 Financial Performance
9.4.3 Gastric Cancer Pipeline
9.4.4 SWOT Analysis
9.5 Eli Lilly and Company
9.5.1 Business Description
9.5.2 Financial
